Insulet's stock soared 10% on strong Q3 results and raised sales outlook due to Omnipod's success. Revenue grew 26% YoY, with a 23% and 36% increase in U.S. and International sales.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Insulet's stock soared 10% on strong Q3 results and raised sales outlook due to Omnipod's success. Revenue grew 26% YoY, with a 23% and 36% increase in U.S. and International sales.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.